Neurocytoma,a rare brain tumor,is characterized by a mass located mainly in cerebral ventricles.It is prone to be misdiagnosed as oligodendroglioma or ependymoma due to their similar histopathological features in clin...Neurocytoma,a rare brain tumor,is characterized by a mass located mainly in cerebral ventricles.It is prone to be misdiagnosed as oligodendroglioma or ependymoma due to their similar histopathological features in clinical practice.This study aimed to examine the clinicopathological features and differential diagnosis of central and extraventricular neurocytoma.The clinical and histopathological data of 17 patients (male:female=7:10;age:4-41 years;mean age:27.4 years) with central or extraventricular neurocytoma were retrospectively analyzed.These patients showed typical radiological,histopathological and immunohistochemical features of neurocytoma.The tumor tissue was found to be composed of small uniform cells with round nuclei and clear cytoplasm resembling that of oligodendroglioma and ependymoma.Immunohistochemistry revealed the tumor tissues were positive for neuronal markers such as synaptophysin (SYN) and neuronal nuclear antigen (NeuN).It was concluded histopathological features of neurocytoma overlaps with some tumors in the central neural system.Immunopositivity for SYN and NeuN can help differentially diagnose neurocytoma.展开更多
Central neurocytoma （CN）, first described by Hassoun et al in 1982, is a rare neuronal tumor of the centralnervous system, and accounts for 0.25%-0.5% of all intracranial tumors. CN commonly occurs as an intraventri...Central neurocytoma （CN）, first described by Hassoun et al in 1982, is a rare neuronal tumor of the centralnervous system, and accounts for 0.25%-0.5% of all intracranial tumors. CN commonly occurs as an intraventricular mass but may also occur as a periventricular parenchymal mass or even in locations remote from the ventricles, in which case it is termed as an extraventricular neurocytoma （EVN） （cerebral）. EVNs show a wide variability with regard to morphologic features, cellularity, and proliferation rate and are more frequently associated with poorer clinical outcomes than CNs. 1 To our knowledge, little is known regarding the treatment of atypical neurocytomas.展开更多
目的分析颅内脑室外室管膜瘤(intracranial extraventricular ependymoma,IEE)患者术前伦勃朗视觉感受图像(visually accessible Rembrandt images,VASARI)特征表现,探讨基于VASARI特征的视觉评估在预测颅内脑室外室管膜瘤世界卫生组织(...目的分析颅内脑室外室管膜瘤(intracranial extraventricular ependymoma,IEE)患者术前伦勃朗视觉感受图像(visually accessible Rembrandt images,VASARI)特征表现,探讨基于VASARI特征的视觉评估在预测颅内脑室外室管膜瘤世界卫生组织(World Health Organization,WHO)分级及Ki-67增殖指数的价值。材料与方法回顾性分析2012年1月至2024年9月兰州大学第二医院进行手术切除并经病理证实的30例IEE患者(WHO 2级18例,3级12例)的临床及术前头颅MRI资料。由两名经验丰富的神经影像医师根据VASARI标准对IEE患者的MRI特征进行评估,通过SPSS 27.0软件分析VASARI特征与WHO分级及Ki-67增殖指数的相关性,同时运用受试者工作特征(receiver operating characteristic,ROC)曲线来评估其诊断效能。结果WHO 3级组的VASARI总分(92.00±18.75)显著高于2级组(76.22±18.89,P<0.05)。根据ROC分析结果,VASARI总分鉴别WHO 3级与2级室管膜瘤的曲线下面积(area under the curve,AUC)为0.736(95%CI:0.541~0.931),最佳截断值(cut-off值)≥59.5时敏感度达到94.1%,特异度为30.8%。两组病例在肿瘤囊变率(F8)、强化边缘厚度(F11)和瘤周水肿比例(F14)等特征上差异有统计学意义(P<0.05),其中WHO 3级肿瘤表现出了更高的囊变率、更厚的强化边缘以及更显著的瘤周水肿。VASARI总分与WHO分级(r=0.391,P=0.032)及Ki-67增殖指数(r=0.370,P=0.044)均呈正相关,其预测Ki-67高表达的AUC为0.633(95%CI:0.421~0.845),最佳截断值cut-off值)≥76.5时敏感度为69.2%,特异度为82.4%。结论VASARI MRI特征(F8、F11、F14及总分)对术前无创区分WHO 2级与3级IEE及预测Ki-67增殖指数具有一定价值,可作为辅助评估工具为临床诊疗提供参考。展开更多
目的探讨少见部位的脑室外神经细胞瘤(EVN)的MRI影像表现。资料与方法搜集经病理证实的EVN患者资料共4例,回顾性分析其术前MRI影像表现。结果 4例中,2例位于颈髓,呈囊实性改变,T1WI呈等或稍高信号,T2WI呈稍高信号,1例病灶内可见出血并...目的探讨少见部位的脑室外神经细胞瘤(EVN)的MRI影像表现。资料与方法搜集经病理证实的EVN患者资料共4例,回顾性分析其术前MRI影像表现。结果 4例中,2例位于颈髓,呈囊实性改变,T1WI呈等或稍高信号,T2WI呈稍高信号,1例病灶内可见出血并伴有继发性脊髓空洞;2例位于颅底,均以实性肿块为主,信号欠均匀,T1WI呈稍低信号,T2WI呈稍高信号。4例肿瘤内均可见多发的流空血管。增强后4例肿瘤呈不均匀中～重度强化。结论 EVN MRI表现有一定的特征,鉴别诊断中应考虑该病可能。展开更多
The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Al...The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique（INET） consists of two of our patented inventions： a transparent sheath（Patent No. ZL 200820046232.0） and a hematoma aspirator（Patent No. ZL 201520248717.8）. This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35（19 men and 16 women, aged 53.2 ± 8.7 years） in the INET group and 30（17 men and 13 women, aged 51.5 ± 7.9 years） in the control group（extraventricular drainage plus urokinase thrombolytic therapy）. Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov（NCT02515903）.展开更多
文摘Neurocytoma,a rare brain tumor,is characterized by a mass located mainly in cerebral ventricles.It is prone to be misdiagnosed as oligodendroglioma or ependymoma due to their similar histopathological features in clinical practice.This study aimed to examine the clinicopathological features and differential diagnosis of central and extraventricular neurocytoma.The clinical and histopathological data of 17 patients (male:female=7:10;age:4-41 years;mean age:27.4 years) with central or extraventricular neurocytoma were retrospectively analyzed.These patients showed typical radiological,histopathological and immunohistochemical features of neurocytoma.The tumor tissue was found to be composed of small uniform cells with round nuclei and clear cytoplasm resembling that of oligodendroglioma and ependymoma.Immunohistochemistry revealed the tumor tissues were positive for neuronal markers such as synaptophysin (SYN) and neuronal nuclear antigen (NeuN).It was concluded histopathological features of neurocytoma overlaps with some tumors in the central neural system.Immunopositivity for SYN and NeuN can help differentially diagnose neurocytoma.
文摘Central neurocytoma （CN）, first described by Hassoun et al in 1982, is a rare neuronal tumor of the centralnervous system, and accounts for 0.25%-0.5% of all intracranial tumors. CN commonly occurs as an intraventricular mass but may also occur as a periventricular parenchymal mass or even in locations remote from the ventricles, in which case it is termed as an extraventricular neurocytoma （EVN） （cerebral）. EVNs show a wide variability with regard to morphologic features, cellularity, and proliferation rate and are more frequently associated with poorer clinical outcomes than CNs. 1 To our knowledge, little is known regarding the treatment of atypical neurocytomas.
文摘目的分析颅内脑室外室管膜瘤(intracranial extraventricular ependymoma,IEE)患者术前伦勃朗视觉感受图像(visually accessible Rembrandt images,VASARI)特征表现,探讨基于VASARI特征的视觉评估在预测颅内脑室外室管膜瘤世界卫生组织(World Health Organization,WHO)分级及Ki-67增殖指数的价值。材料与方法回顾性分析2012年1月至2024年9月兰州大学第二医院进行手术切除并经病理证实的30例IEE患者(WHO 2级18例,3级12例)的临床及术前头颅MRI资料。由两名经验丰富的神经影像医师根据VASARI标准对IEE患者的MRI特征进行评估,通过SPSS 27.0软件分析VASARI特征与WHO分级及Ki-67增殖指数的相关性,同时运用受试者工作特征(receiver operating characteristic,ROC)曲线来评估其诊断效能。结果WHO 3级组的VASARI总分(92.00±18.75)显著高于2级组(76.22±18.89,P<0.05)。根据ROC分析结果,VASARI总分鉴别WHO 3级与2级室管膜瘤的曲线下面积(area under the curve,AUC)为0.736(95%CI:0.541~0.931),最佳截断值(cut-off值)≥59.5时敏感度达到94.1%,特异度为30.8%。两组病例在肿瘤囊变率(F8)、强化边缘厚度(F11)和瘤周水肿比例(F14)等特征上差异有统计学意义(P<0.05),其中WHO 3级肿瘤表现出了更高的囊变率、更厚的强化边缘以及更显著的瘤周水肿。VASARI总分与WHO分级(r=0.391,P=0.032)及Ki-67增殖指数(r=0.370,P=0.044)均呈正相关,其预测Ki-67高表达的AUC为0.633(95%CI:0.421~0.845),最佳截断值cut-off值)≥76.5时敏感度为69.2%,特异度为82.4%。结论VASARI MRI特征(F8、F11、F14及总分)对术前无创区分WHO 2级与3级IEE及预测Ki-67增殖指数具有一定价值,可作为辅助评估工具为临床诊疗提供参考。
文摘目的探讨少见部位的脑室外神经细胞瘤(EVN)的MRI影像表现。资料与方法搜集经病理证实的EVN患者资料共4例,回顾性分析其术前MRI影像表现。结果 4例中,2例位于颈髓,呈囊实性改变,T1WI呈等或稍高信号,T2WI呈稍高信号,1例病灶内可见出血并伴有继发性脊髓空洞;2例位于颅底,均以实性肿块为主,信号欠均匀,T1WI呈稍低信号,T2WI呈稍高信号。4例肿瘤内均可见多发的流空血管。增强后4例肿瘤呈不均匀中～重度强化。结论 EVN MRI表现有一定的特征,鉴别诊断中应考虑该病可能。
基金funded by a grant from the Clinical Research Project of Shenzhen Health and Family Planning Commission in China,No.SZLY2018007a grant from the Science and Technology Planning Project of Shenzhen City of China,No.JCYJ 20150403101028210+2 种基金a grant from the Science and Technology Development and Cultivation Project of Southern Medical University of China,No.KJ 20161115the Guangdong Provincial Medical Research Fund in China,No.A2016545the Shenzhen Health Planning Commission Research Fund in China,No.201601013,201506009
文摘The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique（INET） consists of two of our patented inventions： a transparent sheath（Patent No. ZL 200820046232.0） and a hematoma aspirator（Patent No. ZL 201520248717.8）. This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35（19 men and 16 women, aged 53.2 ± 8.7 years） in the INET group and 30（17 men and 13 women, aged 51.5 ± 7.9 years） in the control group（extraventricular drainage plus urokinase thrombolytic therapy）. Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov（NCT02515903）.
